Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

82.71USD
12:11pm EDT
Change (% chg)

$-0.48 (-0.58%)
Prev Close
$83.19
Open
$83.41
Day's High
$84.38
Day's Low
$82.56
Volume
377,168
Avg. Vol
--
52-wk High
--
52-wk Low
--

LLY.N

Chart for LLY.N

About

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company's products are sold in approximately 120 countries. The Company's human pharmaceutical business segment... (more)

Overall

Beta: 0.27
Market Cap(Mil.): $92,219.48
Shares Outstanding(Mil.): 1,108.54
Dividend: 0.50
Yield (%): 2.40

Financials

  LLY.N Industry Sector
P/E (TTM): 43.18 35.90 36.13
EPS (TTM): 1.93 -- --
ROI: 7.44 15.37 14.83
ROE: 12.61 15.94 15.69
Search Stocks

CORRECTED-BRIEF- Eli Lilly and Co says EMPA-REG OUTCOME met its primary endpoint

Aug 20 - Eli Lilly and Co : * Jardiance demonstrated cardiovascular (cv) risk reduction in people with type 2 diabetes at high risk for cv events * Says empa-reg outcome met its primary endpoint * Says empa-reg outcome demonstrated superiority of jardiance, when added to standard of care, in cv risk reduction * Source text for Eikon * Further company coverage

20 Aug 2015

Eli Lilly shifts Alzheimer-drug study to USC

- Pharmaceutical giant Eli Lilly announced Tuesday it will shift the funding for clinical trials of an early-stage Alzheimer's treatment from the University of California San Diego to the University of Southern California. The study of solanezumab is a large part of the Alzheimer's Disease Cooperative Study, a $100 million, 70-member consortium that has been headquartered at UCSD since its inception in 1991.

06 Aug 2015

Lilly sales inch up on demand for animal health, new drugs

July 23 - Eli Lilly and Co said its quarterly revenue rose about 1 percent, helped by demand for its new cancer and diabetes treatments and the acquisition of Novartis AG's animal health business.

23 Jul 2015

Britain's Immunocore raises $320 mln in record financing round

DUBLIN, July 16 - Britain's Immunocore completed Europe's largest ever financing round by a private life sciences company on Thursday, raising $320 million from investors including Eli Lilly & Co, Malin and Woodford Investment Management.

16 Jul 2015

BRIEF-British biotech firm Immunocore to raise $320 mln in finance

* British biotech firm immunocore says secures $320 million in Europe's largest private life sciences financing

16 Jul 2015

Lilly cancer drug improves survival, raises blood clot risk: FDA

WASHINGTON - Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots, according to a preliminary review by the U.S. Food and Drug Administration.

07 Jul 2015

FDA asks panel to weigh benefit, risk of Lilly lung cancer drug

July 7 - Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots according to a preliminary review by the U.S. Food and Drug Administration.

07 Jul 2015

US STOCKS-Wall St little changed; health stocks rally

* Indexes up: Dow 0.06 pct, S&P 0.13 pct, Nasdaq 0.14 pct (Updates to early afternoon)

25 Jun 2015

New Issue- Eli Lilly prices a triple tranche deal

where assigned, and hit the newskey (F9 on Reuters terminals)

26 May 2015

DIARY-U.S. MEETINGS/WEEK AHEAD

Thomson Reuters April 27, 2015 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - MONTH AHEAD Dividends Non S&P 500 - Weekly Federal Reserve events ConferenceCall/Webcast - Weekly Meetings - Weekly Xtra users can see more details on conference calls & webcasts by hovering your mouse over the RIC, right click, no click on Related Co Data, now click on Co Events.

27 Apr 2015

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Wright Reports
$75.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks